“Statins cause more harm than good, so people at risk of heart disease should avoid them or stop taking them.”
An editorial question about whether statin risks outweigh their benefits for people at risk of heart disease.
A systematic review describes statins as a cornerstone of cardiovascular prevention and reports evidence that lowering LDL cholesterol reduces cardiovascular events. It also reviews potential harms, including muscle symptoms, liver effects and a modest increase in diabetes risk. Muscle complaints are reported more often in observational studies than in randomised trials, where the difference from placebo is small. These sources do not establish that statins cause more harm than good overall, but they also do not assess an individual’s balance of benefits and risks.
If you are worried about side effects or unsure whether a statin is right for you, what would help you discuss its possible benefits and risks with your doctor?
Advances in statin adverse reactions and the potential mechanisms: A systematic review - PMC · Source document
The source exceeds the research excerpt. Check the full linked document before drawing clinical conclusions. The source exceeds the research excerpt. Check the full linked document before drawing clinical conclusions.
The Role of Exercise in Statin-Associated Muscle Symptoms Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - PMC · Source document
The source exceeds the research excerpt. Check the full linked document before drawing clinical conclusions. The source exceeds the research excerpt. Check the full linked document before drawing clinical conclusions.
Evidence checked November 04, 2026 · Reviewed November 04, 2026
Curated topic researched on demand from indexed public sources, not platform-wide monitoring. Attention and prevalence are not measured; the claim itself is editorial. Some searches or retrievals failed; review the research scope before publishing.
What changed
November 04, 2026 A systematic review describes statins as a cornerstone of cardiovascular prevention and reports evidence that lowering LDL cholesterol reduces cardiovascular events. It also reviews potential harms, including muscle symptoms, liver effects and a modest increase in diabetes risk. Muscle complaints are reported more often in observational studies than in randomised trials, where the difference from placebo is small. These sources do not establish that statins cause more harm than good overall, but they also do not assess an individual’s balance of benefits and risks.
November 03, 2026 A 2024 systematic review reports that each 1 mmol/L reduction in LDL cholesterol is associated with about a 20% reduction in cardiovascular events, while recognising possible muscle, liver, kidney and blood-glucose effects. Muscle symptoms are commonly reported in observational studies, but the review notes much smaller differences between statin and placebo in randomised trials. An exercise-focused review found only five eligible, short-term trials, too few to resolve muscle-symptom risk during exercise.
GPT-6 Luna The blanket claim is not supported by these documents: they describe cardiovascular benefit alongside recognised possible harms. The evidence supplied is not a complete assessment of every patient group or individual risk profile. Concerns about side effects deserve attention, but this claim alone is not a reason to stop treatment without discussing options with a clinician.
DeepSeek V4.1 Flash The claim is not supported. The review describes statins as first-line therapy that cuts cardiovascular events by about 20% per 1 mmol/L LDL reduction, with adverse reactions mostly uncommon; muscle symptoms are the main issue but placebo-controlled trials show little difference from placebo, suggesting a nocebo effect. It notes statin intolerance in some patients, so monitoring and management are needed, not avoidance. The exercise review found only a small, non-significant excess of muscle symptoms with statins. Neither document supports stopping statins; decisions should be individualised with a clinician.
Grok 4.7 The claim is not supported. Both reviews describe real harms, including muscle symptoms, liver effects, and diabetes risk, and note that intolerance can reduce adherence. They also report substantial benefit: roughly a 20 to 22 percent reduction in cardiovascular events for each 1 mmol/L fall in LDL cholesterol. Muscle symptoms are much less common in blinded trials than observational reports, with many attributed to nocebo effects. These sources do not show net harm or support avoiding or stopping statins in people at heart-disease risk. Do not stop treatment abruptly without clinical review.
